Related Experiment Video
Updated: Jun 10, 2026
08:48
Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models
Published on: June 30, 2023
Mitochondrial Drugs for Alzheimer Disease
David J Bonda1, Xinglong Wang, Katarzyna A Gustaw-Rothenberg
1Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Pharmaceuticals (Basel, Switzerland)
|July 27, 2010
Summary
Current Alzheimer disease (AD) treatments slow progression but do not halt it. This review explores targeting neuronal mitochondria to prevent AD, focusing on repair and protection strategies for disease modification.
Area of Science:
- Neuroscience
- Cell Biology
- Pathology
Background:
- Alzheimer disease (AD) treatments currently lack disease-modifying effects, failing to halt neurodegeneration and cognitive decline.
- Mitochondria, central to cellular metabolism and reactive oxygen species generation, are implicated in cellular damage.
- Mitochondrial dysfunction precedes hallmark AD pathologies, suggesting a key role in disease pathogenesis.
Purpose of the Study:
- To review the role of neuronal mitochondria in Alzheimer disease (AD) pathogenesis.
- To critically assess therapeutic strategies targeting mitochondria for AD prevention.
- To explore the potential of mitochondrial repair and protection as a disease-modifying approach.
Main Methods:
- Literature review focusing on the role of mitochondria in AD.
- Analysis of existing and potential therapeutic strategies targeting mitochondrial function.
- Assessment of oxidative stress and mitochondrial damage in AD etiology.
Main Results:
- Mitochondrial defects and oxidative stress are significant contributors to neuronal damage in AD.
- Mitochondrial dysfunction is an early event in AD pathogenesis.
- Targeting mitochondria offers a promising upstream access point for therapeutic intervention.
Conclusions:
- Neuronal mitochondria play a critical role in Alzheimer disease (AD) pathogenesis.
- Focusing on mitochondrial repair and protection presents a realistic strategy for developing effective AD therapeutics.
- Targeting mitochondria may offer a disease-modifying effect currently lacking in AD treatment.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...